BRAF and melanoma: BRAF inhibitors target specific mutations of BRAF in the kinase domain, which are present in about 50% of melanomas and cause over-activation of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway, involved in cell proliferation/survival.